Bionano Genomics, Inc. Announces Executive Changes, Effective September 1, 2020
August 26, 2020 at 08:07 am EDT
Share
Effective as of September 1, 2020, Bionano Genomics, Inc. appointed Christopher Stewart as Chief Financial Officer of the Company. Mr. Stewart will also serve as the Company's principal financial officer and principal accounting officer, replacing R. Erik Holmlin, Ph.D. and Mark Adamchak, the Company's Chief Executive Officer and Controller, respectively, who have been serving in those roles while the Company searched for a Chief Financial Officer. Mr. Stewart brings more than 20 years of finance, accounting and strategic planning experience at companies ranging from startups to large public companies. Prior to joining the Company, Mr. Stewart served as the Head of the Maxwell Ultracapacitors business unit following its acquisition by Tesla, Inc., starting in May 2019.
Bionano Genomics, Inc. is a genomics company. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. Through Lineagen, Inc., the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).
BIONANO GENOMICS, INC. 
